Biotech, Patents, RNA Interference
Alnylam Loses Patent Dispute in Europe
Luke Timmerman 1/20/09
Cambridge, MA-based Alnylam Pharmaceuticals, a leading developer of drugs using RNA interference technology, said today it lost an oral argument that it should be granted a particular patent in Europe from its Kreutzer-Limmer patent estate. The final decision on the patent, known as ‘945, is still subject to further appeal, Alnylam said in a statement. Still, the company’s shares (NASDAQ: ALNY) fell 10 percent to $20.70 at 2:50 pm Eastern time.
Luke Timmerman is the National Biotechnology Editor for Xconomy. You can e-mail him at ltimmerman@xconomy.com, call 206-624-2374, or follow him on Twitter at http://twitter.com/ldtimmerman.
